相关实验视频
Updated: Jul 21, 2025
08:39
Murine Colitis Modeling using Dextran Sulfate Sodium DSS
Published on: January 19, 2010
50.0K
沙利德化物通过调节肠道微生物群,缓解了小鼠的硫酸诱导的大肠炎
Jiuxi Liu1,2, Jiapei Cai1, Peng Fan1
1Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Jilin University, 130062 Changchun, People's Republic of China. ygcao82@jlu.edu.cn.
Food & function
|July 28, 2023
概括
沙利德 (Sal) 通过恢复肠道微生物群平衡,有效治疗炎症性肠病 (IBD). 这种功能性食物候选物可以缓解结肠炎症状,并减少小鼠的炎症.
科学领域:
- 胃肠病学 胃肠病学
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肠道失调是炎症性肠病 (IBD) 进展的关键驱动因素.
- 目前对IBD的治疗方法往往存在局限性,需要探索新的治疗药物.
- 化 (Sal),一种来自Rhodiola rosea* L.的化合物,已经显示出潜在的抗炎性质.
研究的目的:
- 调查沙利德 (Sal) 在改善硫酸 (DSS) 诱导的大肠炎方面的疗效.
- 为了确定Sal的治疗效果是否通过调节肠道微生物群来调节.
- 探索Sal作为一种潜在的功能性食物,用于治疗大肠炎.
主要方法:
- 在小鼠中使用DSS诱导大肠炎,随后口服Sal.
- 通过结肠长度,组织学分析和疾病活动指数 (DAI) 评分来评估结肠炎的严重程度.
- 从接受Sal治疗的供体中进行便微生物群移植 (FMT),以评估因果关系和肠道微生物群分析 (16S rRNA测序).
- 评估肠道屏障完整性标记物 (mucin-2,ZO-1,ocludin) 和巨细胞极化.
- 抗生素诱导的肠道微生物群枯竭,以证实微生物群依赖的影响.
主要成果:
- 口服Sal治疗显著抑制了DSS诱导的大肠炎,改善了结肠长度,组织学和DAI得分.
- 盐的使用部分恢复了结肠小鼠的肠道微生物群组成.
- 接受Sal治疗的捐赠者的FMT减轻了肠炎症状,并改善了接受小鼠的肠道屏障功能.
- 盐和FMT调节的肠道微生物群,减少了Turicibacter,Alistipes,Romboutsia和增加了Lactobacillus的丰度.
- 在肠道微生物群枯竭后,Sal的抗炎作用被废除,证实了微生物群依赖的机制.
结论:
- 沙利化物 (Sal) 在改善小鼠DSS诱导的大肠炎方面显示出显著的治疗潜力.
- 盐的有益作用通过调节肠道微生物群的组成和功能来调节.
- 盐改善了肠道屏障的完整性,并减少了肠道炎症,使其成为功能性食品应用在结肠炎管理中的有希望的候选人.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
175
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
175
01:17Drugs for Treatment of Diarrhea-Predominant IBS
214
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
214
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
311
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
311